1.	A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-03, NCT01212991
2.	A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0111, NCT01284920
3.	A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0222, 2010-021868-15, NCT01288911
4.	Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-07, NCT01547299
5.	A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0011, NCT01650194
6.	Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-09, NCT01664923
7.	Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-08, NCT01597193